CMMB vs ROMA Comparison

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage and overcome various business matters arising from such factors related to ESG, sustainability and climate change. it provides tailored-made sustainability solutions to meet the client's specific needs. Its mission is to provide its clients with a one-stop destination for high-quality and holistic sustainability and climate change-related consulting services to support a more sustainable, balanced and inclusive future for its clients' organizations and the world.